The April 2015 #radonc journal club will be discussing the article:
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Try tweeting that!
This multicenter phase III trial, RTOG 0617, was designed to answer two questions:
- Does radiation dose escalation above 60 Gray improve cancer control and survival?
- Does cetuximab synergize with radiation to improve outcomes beyond the benefit of standard carboplatin/taxol chemotherapy?
Lead author Dr. Jeffrey Bradley from Washington University will join us. Please follow him on Twitter to keep up with the chat and beyond!
We start asynchronous discussion Friday April 17th at 6 AM Central Standard Time with the live chat on Sunday April 19th from 8-9 PM Central Standard Time.
Here are the topics we will be covering:
T1: What is the role of combined chemotherapy and radiation in treating stage III
non-small cell lung cancer (NSCLC)?
T2a: What is the rationale for higher radiation doses above 60 Gy?
T2b: What is the rationale for adding a third drug as a radiation sensitizer? Why
T3: What were the results of (a) higher radiation dose and (b) adding cetuximab?
T4a: What are future directions for improvement on our current standard?
T4b: What are safe radiation constraints even at standard radiation doses?
Just register with the Lancet and you can read/download the PDF.
Please join us and share what you think!